<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03516955</url>
  </required_header>
  <id_info>
    <org_study_id>SPS-LBN-2014-05</org_study_id>
    <nct_id>NCT03516955</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting</brief_title>
  <official_title>Observational Study of Superstat® (Rosuvastatin) in Hypercholesterolemia Patients in Lebanon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hikma Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hikma Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed the safety and efficacy of generic Rosuvastatin in reducing plasma low&#xD;
      density lipoprotein (LDL) cholesterol in Lebanese adult patients (18 years or older) with&#xD;
      dyslipidemia for both primary and secondary prevention based on their total cardiovascular&#xD;
      risk. No visits or interventions, additional to the routine clinical practice, were requested&#xD;
      or performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An observational, multicenter, prospective study of Lebanese adult (18 years or older)&#xD;
      hypercholesterolemic patients administered generic Rosuvastatin (Superstat®).&#xD;
&#xD;
      Eligible newly diagnosed hypercholesterolemic patients took generic Rosuvastatin as&#xD;
      prescribed by their treating physician. Assigning patients to generic Rosuvastatin was&#xD;
      decided within the current practice and medical indication and was independent from the&#xD;
      recruitment into the study.&#xD;
&#xD;
      Patients were followed-up at the clinic as per the standard practice of care. Each patient&#xD;
      was followed-up for a period of 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in mean low-density lipoproteins (LDL-C)</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in mean total cholesterol, triglycerides, high density lipoprotein (HDL-C)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who meet their target (LDL-C)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of adverse events (AEs) in association with generic rosuvastatin</measure>
    <time_frame>2 months</time_frame>
    <description>Rate of AEs which might include the worsening in baseline medical conditions, the occurrence of new conditions, or a significant change in vital signs or laboratory values.</description>
  </secondary_outcome>
  <enrollment type="Actual">317</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Superstat ® Tablets 10mg, 20mg</description>
    <other_name>Superstat ®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients were recruited from 24 cardiology, endocrinology and general practitioner&#xD;
        outpatient clinics in Lebanon&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females ≥ 18 years of age&#xD;
&#xD;
          -  Patients with dyslipidemia requiring statin therapy according to CV risk factors as&#xD;
             per the ESC/EAS 2011 guidelines for primary or secondary prevention&#xD;
&#xD;
          -  Patients provided written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Statin use in the past 3 months&#xD;
&#xD;
          -  Any contraindication to HMG-CoA reductase inhibitors&#xD;
&#xD;
          -  Co-administration of non-statin lipid lowering agent (ezitimibe, fibrates, niacin,&#xD;
             omega 3)&#xD;
&#xD;
          -  Conditions which may cause secondary dyslipidemia&#xD;
&#xD;
          -  Any of the following abnormal laboratory tests:&#xD;
&#xD;
        TG level of &gt; 400 mg/dL, Abnormal liver enzymes (AST or ALT) ≥ 3 ULN, Abnormal serum&#xD;
        creatine kinase (CK) &gt; 5 ULN&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2018</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superstat</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Statins</keyword>
  <keyword>LDL-C</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

